Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 0 2 AND DEXTROSE 5 IN PLASTIC CONTAINER versus ROPIVACAINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 0 2 AND DEXTROSE 5 IN PLASTIC CONTAINER versus ROPIVACAINE HYDROCHLORIDE.
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER vs ROPIVACAINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is a sodium channel blocker that stabilizes neuronal membranes by inhibiting the ionic fluxes required for initiation and conduction of impulses, thereby producing local anesthesia. Dextrose 5% provides caloric support.
Ropivacaine is an amide-type local anesthetic that reversibly blocks nerve impulse propagation by inhibiting sodium ion influx via voltage-gated sodium channels in neuronal cell membranes.
Intravenous administration: Initial dose of 1-1.5 mg/kg (up to 300 mg total) given at a rate not exceeding 50 mg/min. Followed by continuous infusion at 1-4 mg/min (20-50 mcg/kg/min) for arrhythmia management.
0.2% to 0.5% solution; epidural: 15-30 mg bolus, then 6-14 mg/hour infusion; peripheral nerve block: 0.5% solution, 20-30 mL; local infiltration: 0.2% solution, up to 200 mg total.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours (prolonged to 2–3 hours in hepatic impairment; unchanged in renal impairment).
Terminal elimination half-life: 1.8–2.7 hours (mean 2.0 h) in adults. In neonates, prolonged to 3–6 hours due to immature hepatic clearance.
Renal excretion of unchanged drug and metabolites: 10% unchanged, 90% as metabolites (primarily 4-hydroxy-2,6-xylidine and glycylxylidide). Less than 1% biliary/fecal.
Renal: 86% as metabolites and unchanged drug (primarily 3-hydroxy-ropivacaine and 4-hydroxy-ropivacaine glucuronides). Fecal: <1%. Biliary: minor.
Category A/B
Category A/B
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic